Theranica
- Industry
- Medical Devices
- Founded Year
- 2016
- Headquarters
- Netanya, Israel
- Employee Count
- 50
Key People
- Alon Ironi - Co-Founder and CEO
- Ronny Hermon - Co-Founder and CTO
- Shimon Eckhouse - Chairman
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced MedTech entrepreneurs with a track record of success.
Theranica's leadership includes individuals with significant experience in the medical technology sector, indicating a strong foundation for the company's strategic direction and innovation capabilities.
- Clinical Need
-
Aspect: Very Strong
Summary: Theranica addresses a significant unmet need in migraine treatment with its non-invasive, drug-free solution.
Migraines affect a substantial portion of the population, and existing treatments often have limitations. Theranica's approach offers a novel solution that could significantly improve patient outcomes.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for migraine treatments includes several competitors, but Theranica's unique approach differentiates it.
The migraine treatment market features various pharmaceutical and device-based solutions. Theranica's non-invasive, drug-free device offers a distinct alternative that may appeal to patients seeking different treatment options.
- Technical Challenge
-
Aspect: Predictable
Summary: The development of Theranica's device involves manageable technical challenges with established solutions.
Theranica's device leverages existing neuromodulation technologies, suggesting that the technical challenges are within predictable parameters and can be effectively managed.
- Patent
-
Aspect: Strong
Summary: Theranica holds a robust patent portfolio protecting its technology.
A strong patent portfolio ensures that Theranica's unique technology is safeguarded, allowing the company to maintain a competitive position in the market.
- Financing
-
Aspect: Well-funded
Summary: Theranica has secured substantial funding from reputable investors.
With investments from firms like aMoon and Lightspeed Venture Partners, Theranica is well-positioned financially to advance its product development and market penetration strategies.
- Regulatory
-
Aspect: 510k/PMA
Summary: Theranica's device has received FDA clearance, facilitating market entry.
FDA clearance indicates that Theranica's device meets safety and efficacy standards, which is crucial for gaining trust among healthcare providers and patients.
Opportunity Rollup
- Odds of Success
- 3.7
- Peak Market Share
- 4.7
- Segment CAGR
- 8.51%
- Market Segment
- Neuromodulation Devices
- Market Sub Segment
- Non-Invasive Migraine Treatment Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.70 |
| 3 | 1.64 |
| 4 | 3.29 |
| 5 | 4.70 |
Key Takeaway
Theranica's innovative, non-invasive migraine treatment device positions the company favorably in a growing market with significant unmet needs.